CAS 2233-18-3

4-hydroxy-3,5-dimethylbenzaldehyde

Codes: ELAF-002

Application context (from source-drug indications)

Sclerosing cholangitisElafibranorBiliary cirrhosisElafibranorNon-alcoholic steatohepatitisElafibranorRenal impairmentElafibranorKidney diseaseElafibranorHepatic function declineElafibranor

Source drugs (routes using this intermediate)

Drug	Tier	Expiry
Elafibranor	Tier C — Watch / trade	-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

ElafibranorOriginator routesteps: 3total yield: /

1-(4-(methylthio)phenyl)ethan-1-one→4-hydroxy-3,5-dimethylbenzaldehyde→(E)-3-(4-hydroxy-3,5-dimethylphenyl)-1-(4-(methylthio)phenyl)prop-2-en-1-one→isopropyl 2-bromo-2-methylpropanoate→isopropyl (E)-2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoate

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.